Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
WEBINAR: Optimizing method development for efficiency, throughput and data quality 0 days 21 hours 36 mins 49 secs REGISTER NOW

Spotlight survey on antibody-drug conjugates

14 Apr 2015
General interest

As part of our Spotlight on antibody-drug conjugates (ADCs), Bioanalysis Zone carried out a survey to investigate the techniques used to study ADCs, the issues surrounding their analysis, as well as what the future may hold.

The results can be seen via our infographic. We will also be analyzing the results of the survey during our Spotlight panel discussion, which you can register for here.

 

Top content

  • Webinar Q&A follow-up: A masterclass in advanced analytical assays for bioanalysis of oligonucleotides
  • New AI tool predicts multiple sclerosis drug response
  • Waters upgrade Xevo MRT performance: who doesn’t want sharper, faster imaging?

Related tags

ADCs
Previous article

Related articles

11 AUG 2015 CLINICAL
Biotransformation and stability of antibody–drug conjugates: payload metabolism and linker cleavage delineation
31 MAR 2015 GENERAL INTEREST
Antibody–drug conjugates
20 MAY 2015 GENERAL INTEREST
Application note: Development of integrated informatics workflows for the automated assessment of comparability for antibody-drug conjugates (ADCs) using LC-UV and LC-UV/MS (Waters Corporation)
10 AUG 2016 JOURNAL ARTICLES
Outsource-ability of high-resolution MS-based DMPK assays
20 FEB 2015 GENERAL INTEREST
Waters and Ferring collaborate to host Peptide Bioanalysis Forum
20 MAR 2025 CONFERENCE REPORTS
Highlights from the 16th Japan Bioanalysis Forum Symposium
  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
  • Accessibility

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone